No abstract

ObjectivesThis study was designed to evaluate effects of hyperbaric oxygen (HBO) plus 3-aminobenzamide (3-AB) cotreatment on tissue oxidative stress parameters (TOSp), tissue histopathology scores (THSc), and bacterial translocations (Bact-Trans) in an experimental model of severe acute pancreatitis (AP).MethodsSeventy-five Sprague-Dawley rats were randomized into 5 groups. Group 1 received sham. Severe AP was induced by intraductal taurocholate infusion and then group 2 received saline, group 3 received 3-AB, group 4 received 3-AB plus HBO, and group 5 received HBO. 3-Aminobenzamide (10 mg/kg per day, once daily, intraperitoneal) and saline (1 mL/kg) were started right after the induction, whereas HBO (2,8 atm pressure, BID, 90 minutes each) was started at the sixth hour. The rats were euthanized at the 54th hour, and TOSp, THSc, and Bact-Trans were studied.ResultsIn treatment groups 3 and 5, Bact-Trans (P < 0.05, P < 0.05), TOSp (P < 0.05, P < 0.05), and THSc (P < 0.001, P < 0.001) were significantly lower than controls. In addition to these findings, group 4 (cotreatment) showed the most significant effect on Bact-Trans and THSc (P < 0.001, P < 0.001) and also better in TOSp (P < 0.02).ConclusionsPoly(ADP-ribose) polymerase inhibition by 3-AB and HBO treatment alone was effective in the course of severe AP, and favorable with cotreatment because of the improved cascades of inflammatory process by different aspects.

There has been an increasing multiple drug resistance problem in Vibrio cholerae biotype Eltor, the causative agent of 7th pandemic. The aim of this study was to show in vitro and in vivo susceptibility and effectiveness of quinolones in the treatment of endemic cholera cases. Excellent results were obtained in 53 bacteriologically confirmed cholera patients treated with short-term ofloxacin and ciprofloxacin. To our knowledge, there has been no previous report on this subject in the international medical literature. Our results show that quinolones can be an alternative drug for the treatment of multiply resistant V. cholerae infections.

AIM:To investigate the individual and combined effects of allopurinol and hyperbaric oxygen (HBO) therapy on biochemical and histopathological changes, oxidative stress, and bacterial translocation (BT) in the experimental rat acute pancreatitis (AP). METHODS:Eighty-five Sprague-Dawley rats were included in the study. Fifteen of the eighty-five rats were used as controls (sham, GroupⅠ). AP was induced via intraductal taurocholate infusion in the remaining seventy rats. Rats that survived to induction of acute necrotizing pancreatitis were randomized into four groups. Group Ⅱ received saline, Group Ⅲ allopurinol, Group Ⅳ allopurinol plus HBO and Group Ⅴ HBO alone. Serum amylase levels, oxidative stress parameters, BT and histopathologic scores were determined. RESULTS:Serum amylase levels were lower in Groups Ⅲ, Ⅳ and Ⅴ compared to Group Ⅱ (974 ± 110, 384 ± 40, 851 ± 56, and 1664 ± 234 U/L, respectively, P < 0.05, for all). Combining the two treatment options revealed significantly lower median [25-75 percentiles] histopathological scores when compared to individual administrations (13 [12.5-15] in allopurinol group, 9.5 [7-11.75] in HBO group,[6][7].5] in combined group, P < 0.01). Oxidative stress markers were significantly better in all treatment groups compared to the controls. Bacterial translocation into the pancreas and mesenteric lymph nodes was lower in Groups Ⅲ, Ⅳ and Ⅴ compared to Group Ⅱ (54%, 23%, 50% vs 100% for translocation to pancreas, and 62%, 46%, 58% vs 100% for translocation to mesenteric lymph nodes, respectively, P < 0.05 for all). CONCLUSION:The present study confirms the benefit of HBO and allopurinol treatment when administered separately in experimental rat AP. Combination of these treatment options appears to prevent progression of pancreatic injury parameters more effectively.

Aim: Following implementation of Improvement Outcome Guidance (IOG), pancreatic cancer surgery is now mostly performed in major pancreatic referral centers. This may have affected selection for surgery and outcome. We report the effect on workload and mortality rate of centralizing pancreatic surgery for a population of about 3.5 millions to a single Centre. Method: We reviewed activity in 2003 and 2007 (before and after implementation of IOG). Pancreatic surgery was done in 3 hospitals in 2003. In 2007 centralization affected 2.3M population form January, and an additional 1.2M from April 2007. Before centralization the surgical HDU was expanded from 3 to 8 beds. Results: In 2003, there were 67 pancreatic procedures of all types performed by 7 surgeons. In 2007 102 patients diagnosed with a neoplasm were deemed operable, and underwent laparotomy. Only one patient on a cancer pathway failed to meet the 62 day target. Two patients were found to be inoperable, and had palliative bypass. Three surgeons performed 100 resections. A further 10 patients had pancreatic necrosectomy. Of the elective resections 94% were managed in surgical HDU (level 2 critical care). Neo-adjuvant treatment was attempted in 12 borderline pancreatic cancers, 4 were successfully resected, 3 are currently receiving chemotherapy, and in 5 cases there was no improvement and palliative chemoYradio therapy was stopped. Conclusion: Centralization has increased the numbers of patients in this Network offered pancreatic resection for tumor. This has enabled new approaches such as laparoscopic distal pancreatectomy and neoadjuvant treatment for borderline resectable tumors. The inoperability rate is low. Despite wider indications for surgery, the mortality rate has fallen. We conclude that centralization has enabled more patients to benefit from safe surgery for pancreatic neoplasm. emerged as a treatment for pancreatic cancer. One decade has elapsed since its institution. The aim of the study is to detect whether adjuvant G improves survival. Methods: A prospective surgical database from 1985 to 2007 with 1637 records was reviewed and identified 579 patients who underwent resection for PDAC. Median, mean and 1, 3, and 5 year survival were calculated for the entire group; by decades regardless of adjuvant treatment; and by treatment with or without G. Results: The 1, 3 and 5 year survival of resected patients (579) was 66, 26 and 15% respectively, with a mean of 30.8 mo. No significant differences were identified over two decades. Patients who received G (n = 199, 34.5%) compared to NG (n = 379, 65.6%) had a statistically significant increase in survival at 1(80 vs. 55%), 3(35 vs. 20%) and 5(20 vs. 12%) years, with a mean of 37 vs. 27.6 (p G 0.0001). G improved survival in patients with tumors that were moderately differentiated (mean 36.5 vs. 25.5, p G 0.0007), Flavanoids are important components of many fruits and vegetables and are believed to have preventive and therapeutic effects in various human malignancies. We hypothesize that flavanoids may...